You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The deal enables Genosity to add Olink's proteomics technology with next-generation sequencing readout to its repertoire of services.
The deal makes WuXi NextCode the exclusive provider of Olink's proteomics products in China, which the company will offer on a fee-for-service basis.
The study is enrolling up to 2,000 patients at 10 US medical centers and using omics approaches to profile their immune response over the course of a year.
According to the company, the NGS approach will allow it to lower assay costs while increasing its throughput and multiplexing capabilities.
Olink Proteomics' proximity extension assay technology uses oligonucleotide-labeled antibodies to enable multiplex protein measurement.
High throughput and deep coverage have allowed firms like Olink and Somalogic to make inroads, especially among researchers working outside proteomics.
Highlights included mass spec-focused developments like data-independent acquisition and ion mobility along with platforms including Thermo Fisher's Q Exactive.
While the approach lost some of its luster after failing to deliver on early hype, technological improvements are revitalizing interest among researchers.
The incubator, housed on the campus of the Karolinska Institute, draws upon the experience of its partners in genomics, diagnostics, business development, and corporate law.
According to CNBC, Pfizer has announced that its SARS-CoV-2 vaccine data won't be ready this week.
A number of United Nations agencies push for scientific findings to be made accessible through open science.
Paris-Saclay University garners international regard following a decade-long effort to establish the new research university, Nature News reports.
In Nucleic Acids Research this week: database to house IndiGen sequencing data, database of SARS-CoV-2 docking scores, and more.